Positive Results, Close of Public Offerings, Grants, Data Presentations and Partnerships - Research Report on Lexicon, Sangamo

 Positive Results, Close of Public Offerings, Grants, Data Presentations and
Partnerships - Research Report on Lexicon, Sangamo Biosciences, Immunomedics,
                  NewLink Genetics, and Pacific Biosciences

PR Newswire

NEW YORK, October 4, 2013

NEW YORK, October 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Lexicon
Pharmaceuticals, Inc. (NASDAQ: LXRX), Sangamo Biosciences Inc. (NASDAQ: SGMO),
Immunomedics Inc. (NASDAQ: IMMU), NewLink Genetics Corporation (NASDAQ: NLNK),
and Pacific Biosciences of California, Inc. (NASDAQ: PACB). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Lexicon Pharmaceuticals, Inc.Research Report

On October 1, 2013, Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals)
announced that LX4211, a first-in-class, dual inhibitor of sodium glucose
transporters 1 and 2 (SGLT1 and SGLT2), successfully met the primary endpoint
of reducing post-prandial glucose, in a study of patients with type 2 diabetes
and moderate to severe renal impairment. "Our hypothesis was that LX4211 would
improve glycemic control even in patients with the greatest degree of renal
impairment due to its inhibition of SGLT1 in the GI tract," said Pablo
Lapuerta, M.D., Lexicon's Chief Medical Officer. "The post-prandial glucose
reductions and GLP-1 elevations observed in this study population support the
rationale for demonstrating effective HbA1c reduction in a larger, longer-term
Phase 3 trial, and provide further support for the clinical differentiation of
LX4211 as a first-in-class dual SGLT1 and SGLT2 inhibitor." The Full Research
Report on Lexicon Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/b63e_LXRX]

--

Sangamo Biosciences Inc.Research Report

On September 23, 2013, Sangamo BioSciences, inc. (Sangamo BioSciences)
announced the closing of its previously announced underwritten public offering
of 6.1 million shares of its common stock, as well as 915,000 additional
shares pursuant to the full exercise of the over-allotment option given to
underwriters. The Company informed that the shares were sold at the public
offering price of $10.58 per share (the last closing price of the stock on the
date immediately prior to pricing), which broughtthe aggregate gross proceeds
from the offering to approximately $74.2 million, before deducting
underwriting discounts and commissions and other offering expenses. The Full
Research Report on Sangamo Biosciences Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/52a6_SGMO]

--

Immunomedics Inc.Research Report

On September 30, 2013, Immunomedics, Inc. (Immunomedics) announced the
beginning of a three-year grant from the Department of Defense (DOD) valued at
more than $1.6 million, to evaluate milatuzumab as a treatment of patients
with lupus. The Company informed that the clinical trial will be funded by the
Peer Reviewed Medical Research Program of the DOD and will enroll around 30
lupus patients at the Cedars Sinai Medical Center in Los Angeles, CA, under
the direction of Dr. Daniel J. Wallace, the principal clinical investigator of
this project. The Full Research Report on Immunomedics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/c20d_IMMU]

--

NewLink Genetics CorporationResearch Report

On September 30, 2013, NewLink Genetics Corp. (NewLink Genetics) announced the
presentation of data on its lead HyperAcute cancer immunotherapy product
candidates at the 2013 European Cancer Congress (ESMO) in Amsterdam, The
Netherlands. The data showed greater than expected responses to salvage
chemotherapy following treatment with both algenpantucel-L in patients with
pancreatic cancer and tergenpumatucel-L in patients with non-small cell lung
cancer (NSCLC). "These data indicate that pretreatment with HyperAcute
immunotherapy such as algenpantucel-L or tergenpumatucel-L prior to salvage
chemotherapy has the potential to increase the sensitivity of cancer cells to
chemotherapy that may lead to durable objective and complete responses,"
commented Nick Vahanian, MD, President and Chief Medical Officer of NewLink
Genetics. According to the Company, the clinical benefit of
chemo-sensitization is being further investigated in a larger number of
patients by assessing objective tumor responses to follow-on chemotherapy
after HyperAcute immunotherapy in ongoing clinical trials. The Full Research
Report on NewLink Genetics Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/c592_NLNK]

--

Pacific Biosciences of California, Inc.Research Report

On September 25, 2013, Pacific BioSciences of California, Inc. (Pacific
Biosciences) announced that it has entered into an agreement with Roche
Diagnostics for developing diagnostic products, based on the Company's Single
Molecule, Real-Time (SMRT^®) technology. Pacific Biosciences will develop and
manufacture certain products intended for clinical use, which it will sell
exclusively to Roche. Mike Hunkapiller, President and CEO of Pacific
Biosciences said, "As a world leader in in vitro diagnostics, Roche brings
valuable expertise in designing products for clinical use and obtaining
regulatory approvals to sell clinical products in the U.S. and around the
world. We believe the combination of our SMRT Sequencing technology with
Roche's market position and expertise in diagnostics will allow accelerated
commercial success for both companies." The Full Research Report on Pacific
Biosciences of California, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/caf8_PACB]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.